Work in the lab of PS has been supported by Canada Research Chairs, Canada Foundation for Innovation, Alberta Prion Research Institute, Alberta InnovatesNovartis, MS Society of Canada, National MS Society, National Institutes of Health, Canadian Institutes for Health Research, the Hopewell M.I.N.D prize, Alzheimers Society, Barford Foundation, Krembil Foundation, and generous philanthropists
Semaglutide for Weight Loss: GLP-1 Targeting Explained Semaglutide promotes weight loss by acting as a synthetic version of the GLP-1 hormone
RARE SIDE EFFECTS Intrahepatic cholestasis and allergic skin reactions, including photosensitivity and erythroderma may rarely occur (Package insert)
Importantly, CIT levels improve following adherence to a GFD, highlighting its potential as both a diagnostic and prognostic marker in CD (Pascual Prez et al